EE558 The Cost-Effectiveness of Budesonide/Formoterol Maintenance and Reliever Therapy Versus Salmeterol/Fluticasone Plus As-Needed Salbutamol Among Asthma Patients ≥12 Years in China
To evaluate the cost-effectiveness of budesonide/formoterol combination therapy plus as need compared with salmeterol/fluticasone plus salbutamol as reliever therapy for asthma patients ≥12 years from the societal perspective. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: K. Zhou, X. Xie, C. Zuo, Y. Jiang, J. Xuan Source Type: research
EE253 Comparative Efficacy of Beclomethasone/Formoterol/Glycopyrronium (BDP/FOR/GLY) Vs Budesonide/Glycopyrrolate/Formoterol (BUD/GLY/FOR): Indirect Comparison in Chinese Patients with Chronic Obstructive Pulmonary Disease
This study performed an indirect treatment comparison (ITC) of the efficacy of the extrafine SITT with beclomethasone/formoterol/glycopyrronium bromide (BDP/FOR/GLY) versus budesonide/glycopyrrolate/formoterol (BUD/GLY/FOR) for the Chinese COPD patient subgroup. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: M. Orlovic, D. Tzelis, T. Mantopoulos, Y. Punekar, C. Spalding, M. Scott, R. Zhang, F. Xu, A. Madoni Source Type: research
EE103 Cost-Effectiveness Analysis of Single-Inhaler Triple Therapy (FF/UMEC/VI) in COPD Using the Fulfil Trial: China Medical Insurance System Perspective
To assess the cost-effectiveness of single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus budesonide/formoterol (BUD/FOR) for patients with symptomatic COPD and a history of exacerbations from a China medical insurance system perspective based on data from the FULFIL trial (NCT02345161). (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: S.G. Noorduyn, X. Wang, A. Martin, R. Cai, Z. Tang, D. Bointon, A. Sun, A. Ismaila Source Type: research
The effect of different inhaled corticosteroids on airway bacterial load and the microbiome in COPD: a randomized controlled trial
Conclusion: Patients randomized to fluticasone/salmeterol at licensed doses had an increased bacterial load in sputum over time compared to budesonide/formoterol. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Richardson, H., Keir, H. R., Clarke, C., Alferes De Lima, D., Veluchamy, A., Rauchhaus, P., Pembridge, T., Crichton, M., Pollock, J., Finch, S., Dicker, A. J., Billingham, P., Hussain, F., Band, M., Smith, A., Patel, M., Paracha, M., Choudhury, G., Dhasma Tags: Airway pharmacology and treatment Source Type: research
Adherence to single and multiple inhaler triple therapies among patients with COPD in the real world in Japan
Conclusions: Patients with COPD in Japan newly initiating SITT have statistically significantly better adherence compared with patients initiating MITT.Funding: GSK (217615) (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Joksaite, S., Wood, R. P., Mizukami, A., Camidge, L. J., Czira, A., Jennison, T., Ishii, T., Massey, O., Hashimoto, K., Siddiqui, R., Yarita, M., Compton, C., Sharma, R., Ismaila, A. S., Rothnie, K. J. Tags: Airway pharmacology and treatment Source Type: research
Carbon footprint of as-needed budesonide-formoterol in mild asthma: a post hoc analysis
Conclusions: As-needed budesonide-formoterol DPI was associated with a marked reduction in carbon footprint compared with as-needed salbutamol pMDI and compared with maintenance budesonide DPI plus as-needed salbutamol pMDI. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Hatter, L., Bruce, P., Eathorne, A., Holliday, M., Weatherall, M., Beasley, R. Tags: Airway pharmacology and treatment Source Type: research
Switching inhaler treatment from pMDI to DPI in real-world; reduction of carbon footprint
Discussion: The study shows that switching from a pMDI to B-F EH DPI may enhance disease control among patients with asthma, COPD and ACO and at the same time have a positive environmental impact by reducing the carbon footprint of inhaler treatment.1. Tamasi L et al. Adv ther 2018;35:1140-52. 2. MCTOC 2018 Assessment Report p 32. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Janson, C., Vartiainen, V., Hisinger-Mölkänen, H., Lehtimäki, L. Tags: Airway pharmacology and treatment Source Type: research
Asthma medication use in New Zealand following publication of national asthma guidelines
Conclusion: A progressive increase in bud-form dispensing, accompanied by a reduction in SABA and ‘other ICS-LABA’ dispensing, occurred following publication of the 2020 NZ asthma guidelines. These findings suggest that the transition to a bud-form reliever-based stepwise management approach can be achieved at a national level if incorporated in evidence-based guidelines. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Hatter, L., Eathorne, A., Bruce, P., Hills, T., Houghton, C., Weatherall, M., Beasley, R. Tags: Airway pharmacology and treatment Source Type: research
Real-world study of formoterol/budesonide delivered through BAI in COPD patients
Conclusion: Formoterol/budesonide delivered through Synchrobreathe® is effective, safe and preferred by most COPD patients. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Balamurugan, S., Pophale, H., Samariya, U., Apte, K., Singh, S., Dhar, R., Rajan, S., Swarnakar, R., Talwar, D., Lopez, M., Naik, V., Sawant, S., Chhowala, S., Vaidya, A., Gogtay, J. Tags: Airway pharmacology and treatment Source Type: research
Medication success among real-world users of budesonide/glycopyrrolate/formoterol fumarate (BGF) for the management of COPD in a UK primary care population
Conclusions: Patients initiating BGF experienced high levels of real-life medication sucesss & protection against adverse cardiopulmonary events (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Müllerova, H., Chan, J. S. K., Heatley, H., Carter, V., Townend, J., Skinner, D., Franzen, S., Castaneda, J., Marshall, J., Price, D. Tags: Airway pharmacology and treatment Source Type: research
Late Breaking Abstract - SHAMAL: reduction of maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab: a randomised phase 4 study
Conclusion: Benralizumab enabled the majority of SEA patients to maintain disease control and remain exacerbation-free despite a reduction in background therapy to AIR only. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Jackson, D. J., Heaney, L. G., Humbert, M., Kent, B. D., Hiljemark, L., Olinger, L., Cohen, D., Menzies-Gow, A., Korn, S. Tags: Airway pharmacology and treatment Source Type: research
First Real-World Evidence on budesonide/glycopyrronium/formoterol fumarate (BGF) use for COPD patients in France (ENARXI study): an interim analysis
Conclusion: Profile of patients who initiated treatment with BGF was similar between GPs and PNs. Preliminary results regarding more step up from dual therapy for GP and switch from triple therapy for PN may be due to restriction of primary prescription of fixed triple to PN in France. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Deslee, G., Poccardi, N., Fabry-Vendrand, C., Leynaud, D., Thabut, G., Eteve-Pitsaer, C., Coriat, A., Ghout, I., Leleu, H. Tags: General practice and primary care Source Type: research
